

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

**INSIDE INFORMATION
POTENTIAL LOSS IN RELATION TO FUND SUBSCRIPTIONS
AND
ESTABLISHMENT OF INVESTIGATION COMMITTEE**

POTENTIAL LOSS IN RELATION TO FUND SUBSCRIPTIONS

This announcement is made by Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated December 29, 2022 and January 12, 2023, respectively, in relation to the subscriptions in a fund (the “**Announcements**”), the annual report of the Company for the year ended December 31, 2022, the interim report of the Company for the six months ended June 30, 2023, and the annual report of the Company for the year ended December 31, 2023 (the “**2023 Annual Report**”). Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements and the 2023 Annual Report, the Company has subscribed for the Segregated Portfolio, a segregated portfolio of TradArt Flagship Investment SPC (the “**Fund**”) in the aggregate amount of US\$20.0 million (exclusive of transaction costs) and has redeemed US\$0.2 million from the Fund as of the date of this announcement. The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company was recently informed by the Investment Manager of the Fund that, due to the potential default by the issuer (the “**Private Debt Issuer**”) of a private debt in which the Fund invested, the net asset value of the Fund is expected to incur a substantial adverse change (the “**Matter**”). The Board was further informed by the Investment Manager that it has

initiated corresponding measures to the Matter, including appointing an auditor to carry out an audit on the financial information of the Private Debt Issuer. The Company is requesting for a detailed report from the Investment Manager on the updated net asset value of the Fund, including the audited financial information of the Private Debt Issuer. Based on the discussions between the Company and the Investment Manager on July 4, 2024 and the preliminary assessment conducted by the Board, as at the date of this announcement, the Board expects that the Investment Manager is likely to report a substantial loss in the Fund. The Board reserves its right to pursue accountability of the management of the Fund, including the Investment Manager, to recover its losses incurred from the Matter.

ESTABLISHMENT OF INVESTIGATION COMMITTEE

The Board has established an investigation committee (the “**Investigation Committee**”), comprising Dr. Yang Lu (alias Patrick Lu), the Chairman of the Board and an executive Director, and all independent non-executive Directors, namely Dr. Cheung Hoi Yu, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law), to investigate the Matter (the “**Investigation**”). Ms. Monin Ung was appointed as the chairperson of the Investigation Committee. The Investigation Committee may also engage other professional advisers to assist in the Investigation. The duties and purposes of the Investigation Committee include, among others, (i) to carry out the Investigation on the Matter with an aim to report on the events and any issues which led to the Matter; (ii) to report to the Board on the progress and findings of the Investigation in a timely manner; and (iii) to make suggestions to the Board on actions to be taken in respect of the Matter.

To the best of the knowledge, information and belief of the Directors, after having made all reasonable enquiries, as at the date of this announcement, each of the Fund, the Investment Manager and the Private Debt Issuer is an Independent Third Party. Each of the Directors has confirmed that he/she is independent from, and is not connected with, any of the Fund, the Investment Manager, or the Private Debt Issuer.

The Board would like to further supplement that the Group’s research and development activities are on-going, and the management team of the Group is actively carrying out business development and fundraising activities to improve its financial position.

The Company will keep the shareholders of the Company (the “**Shareholders**”) and potential investors informed of any further material developments in connection with the Board's assessment of the financial impact of the Matter on the Company and the results of the Investigation conducted by the Investigation Committee by way of further announcement(s) as and when appropriate and in accordance with the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sirnaomics Ltd.
Yang (Patrick) Lu
Chairman and Executive Director

Hong Kong, July 8, 2024

As at the date of this announcement, the Board comprises Dr. Yang Lu (alias Patrick Lu) and Dr. Xiaochang Dai as executive Directors, Mr. Mincong Huang and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.